Syndesi Therapeutics

📍 Louvain-la-Neuve, Belgium🗓 Founded 2018👥 12 employees💰 Last funded Feb 2018
Biotechnology🌐 syndesitherapeutics.com
Website LinkedIn
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Belgium
1
Netherlands
1
Investor activity2017–2018 · investors recorded per year
2017220181
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Syndesi Therapeutics?
Syndesi Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Syndesi Therapeutics last raise funding?
The most recent investment in Syndesi Therapeutics recorded on gritt.io was in February 2018.
When was Syndesi Therapeutics founded?
Syndesi Therapeutics was founded in 2018.
What industry is Syndesi Therapeutics in?
Syndesi Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Syndesi Therapeutics based?
Syndesi Therapeutics is headquartered in Louvain-la-Neuve, Belgium.